000820505 001__ 820505
000820505 005__ 20240625095121.0
000820505 0247_ $$2doi$$a10.1007/s00894-016-3029-6
000820505 0247_ $$2ISSN$$a0948-5023
000820505 0247_ $$2ISSN$$a1610-2940
000820505 0247_ $$2WOS$$aWOS:000379014700020
000820505 0247_ $$2altmetric$$aaltmetric:9095968
000820505 0247_ $$2pmid$$apmid:27342250
000820505 037__ $$aFZJ-2016-05799
000820505 082__ $$a540
000820505 1001_ $$aNguyen, Tin Trung$$b0
000820505 245__ $$aLigand binding to anti-cancer target CD44 investigated by molecular simulations
000820505 260__ $$aBerlin$$bSpringer$$c2016
000820505 3367_ $$2DRIVER$$aarticle
000820505 3367_ $$2DataCite$$aOutput Types/Journal article
000820505 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1478268519_17704
000820505 3367_ $$2BibTeX$$aARTICLE
000820505 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000820505 3367_ $$00$$2EndNote$$aJournal Article
000820505 520__ $$aCD44 is a cell-surface glycoprotein and receptor for hyaluronan, one of the major components of the tumor extracellular matrix. There is evidence that the interaction between CD44 and hyaluronan promotes breast cancer metastasis. Recently, the molecule F-19848A was shown to inhibit hyaluronan binding to receptor CD44 in a cell-based assay. In this study, we investigated the mechanism and energetics of F-19848A binding to CD44 using molecular simulation. Using the molecular mechanics/Poisson Boltzmann surface area (MM-PBSA) method, we obtained the binding free energy and inhibition constant of the complex. The van der Waals (vdW) interaction and the extended portion of F-19848A play key roles in the binding affinity. We screened natural products from a traditional Chinese medicine database to search for CD44 inhibitors. From combining pharmaceutical requirements with docking and molecular dynamics simulations, we found ten compounds that are potentially better or equal to the F-19848A ligand at binding to CD44 receptor. Therefore, we have identified new candidates of CD44 inhibitors, based on molecular simulation, which may be effective small molecules for the therapy of breast cancer.
000820505 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000820505 588__ $$aDataset connected to CrossRef
000820505 7001_ $$0P:(DE-HGF)0$$aTran, Duy Phuoc$$b1
000820505 7001_ $$0P:(DE-HGF)0$$aHuy, Pham Dinh Quoc$$b2
000820505 7001_ $$0P:(DE-HGF)0$$aHoang, Zung$$b3
000820505 7001_ $$0P:(DE-Juel1)145614$$aCarloni, Paolo$$b4$$eCorresponding author
000820505 7001_ $$0P:(DE-HGF)0$$aVan Pham, Phuc$$b5$$eCorresponding author
000820505 7001_ $$0P:(DE-HGF)0$$aNguyen, Chuong$$b6$$eCorresponding author
000820505 7001_ $$0P:(DE-HGF)0$$aLi, Mai Suan$$b7$$eCorresponding author
000820505 773__ $$0PERI:(DE-600)1284729-x$$a10.1007/s00894-016-3029-6$$gVol. 22, no. 7, p. 165$$n7$$p165$$tJournal of molecular modeling$$v22$$x0948-5023$$y2016
000820505 8564_ $$uhttps://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.pdf$$yRestricted
000820505 8564_ $$uhttps://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.gif?subformat=icon$$xicon$$yRestricted
000820505 8564_ $$uhttps://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000820505 8564_ $$uhttps://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.jpg?subformat=icon-180$$xicon-180$$yRestricted
000820505 8564_ $$uhttps://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.jpg?subformat=icon-640$$xicon-640$$yRestricted
000820505 8564_ $$uhttps://juser.fz-juelich.de/record/820505/files/art_10.1007_s00894-016-3029-6.pdf?subformat=pdfa$$xpdfa$$yRestricted
000820505 909CO $$ooai:juser.fz-juelich.de:820505$$pVDB
000820505 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145614$$aForschungszentrum Jülich$$b4$$kFZJ
000820505 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000820505 9141_ $$y2016
000820505 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000820505 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000820505 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000820505 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000820505 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000820505 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000820505 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000820505 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000820505 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000820505 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ MOL MODEL : 2015
000820505 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000820505 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000820505 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000820505 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000820505 920__ $$lyes
000820505 9201_ $$0I:(DE-Juel1)IAS-5-20120330$$kIAS-5$$lComputational Biomedicine$$x0
000820505 9201_ $$0I:(DE-Juel1)INM-9-20140121$$kINM-9$$lComputational Biomedicine$$x1
000820505 980__ $$ajournal
000820505 980__ $$aVDB
000820505 980__ $$aUNRESTRICTED
000820505 980__ $$aI:(DE-Juel1)IAS-5-20120330
000820505 980__ $$aI:(DE-Juel1)INM-9-20140121
000820505 981__ $$aI:(DE-Juel1)INM-9-20140121